Filter options:

Freebase Commons Common /common

  • Mr. Towarnicki joined Nucleonics as President CEO in 2003. At that time he was also named a member of the board of directors. Prior to Nucleonics, Mr. Towarnicki served as Chairman, President CEO of Cell Pathways, Inc., an emerging pharmaceutical company with two drugs in the clinic and one in-licensed commercial product. Cell Pathways was acquired by OSI Pharmaceuticals in June 2003. During his six-year tenure, Mr. Towarnicki led the expansion of Cell Pathways from a virtual organization to a fully integrated, NASDAQ listed, emerging pharmaceutical company. Prior to joining Cell Pathways, Mr. Towarnicki led the development of Integra LifeSciences Corporation. During his five years as President COO, he built Integra LifeSciences from a 12 person RD organization into a fully integrated medical device company trading on the NASDAQ. Experience prior to Integra LifeSciences includes: General Manager of Focus Technologies, a privately held esoteric disease reference laboratory; VP of Development and Operations for Collagen Corporation; Operations Manager for Pfizer Pharmaceuticals and, ten years of increasing management responsibility in operations for Merck Co. In 2005, Mr. Towarnicki was named to the Biotechnology Industry Organization (BIO) Emerging Companies Section Governing Body. Mr. Towarnicki earned both a B.S. and M.S. in Biology from Villanova University.

Freebase Commons People /people